Cash-strapped Sirnaomics seeks lifeline in cosmetic treatments
The biotech is suing its former CEO over an ill-fated $20 million investment as it pursues a short-term pivot from skin cancer drugs to body-contouring therapies Key Takeaways: After the…
RELATED ARTICLES
-
AI in China’s medical aesthetics sector: From non-core services to clinical device integration
- Extransfer seeks Hong Kong IPO as accounting losses hide a cash cow
- PrimeGenX looks to a Hong Kong IPO as a cure for its cash woes
- Luzhu Biotech braces for make-or-break launch of shingles shot
- Eye drug maker VivaVision feels the strain in IPO funding dash
- Cash-challenged Tenways cycles toward IPO
-
Plummeting cash flow and a stake-trimming top shareholder: What’s up at Zhejiang Shibao?
1057.HK002703.SHE
